Details
Stereochemistry | RACEMIC |
Molecular Formula | C14H15FN2.ClH |
Molecular Weight | 266.742 |
Optical Activity | ( + / - ) |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.CCC1(CC2=CC=C(F)C=C2C1)C3=CNC=N3
InChI
InChIKey=XAGTWPPXXHAZMK-UHFFFAOYSA-N
InChI=1S/C14H15FN2.ClH/c1-2-14(13-8-16-9-17-13)6-10-3-4-12(15)5-11(10)7-14;/h3-5,8-9H,2,6-7H2,1H3,(H,16,17);1H
Molecular Formula | C14H15FN2 |
Molecular Weight | 230.2807 |
Charge | 0 |
Count |
|
Stereochemistry | RACEMIC |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 1 |
E/Z Centers | 0 |
Optical Activity | ( + / - ) |
Molecular Formula | ClH |
Molecular Weight | 36.461 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Fipamezole is a fluorine substituted imidazole compound with high antagonist specificity for the presynaptic alpha2-adrenoceptor. There were no significant differences between the affinity of Fipamezole for the different subtypes, thus characterizing Fipamezole as a non-subtype–selective alpha2 antagonist. Fipamezole had been in phase III clinical trials for the treatment of dyskinesia associated with Parkinson’s disease. Detected side effects are hypertension, nausea, vomiting, dysgeusia, facial flushing.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1867 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12889076 |
9.2 nM [Ki] | ||
Target ID: CHEMBL1942 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12889076 |
17.0 nM [Ki] | ||
Target ID: CHEMBL1916 Sources: https://www.ncbi.nlm.nih.gov/pubmed/12889076 |
55.0 nM [Ki] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
The α₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. | 2010 Oct 15 |
|
Randomized clinical trial of fipamezole for dyskinesia in Parkinson disease (FJORD study). | 2012 Jul 10 |
|
[Pharmacotherapy of Parkinson's disease: progress or regress?]. | 2013 Jul 24 |
|
Non-dopaminergic treatments for motor control in Parkinson's disease. | 2013 Sep |
|
Therapeutic strategies to prevent and manage dyskinesias in Parkinson's disease. | 2015 Feb |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://clinicaltrials.gov/ct2/show/NCT00559871
30 mg, 60 mg or 90 mg three times per day for up to 28 days
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/12889076
Fipamezole had moderate affinity for histamine H1 and H3 receptors and the serotonin (5-HT) transporter (IC50s between 100 nM and 1 uM).
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 05:00:20 UTC 2023
by
admin
on
Sat Dec 16 05:00:20 UTC 2023
|
Record UNII |
441J9148CQ
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
441J9148CQ
Created by
admin on Sat Dec 16 05:00:20 UTC 2023 , Edited by admin on Sat Dec 16 05:00:20 UTC 2023
|
PRIMARY | |||
|
150586-72-4
Created by
admin on Sat Dec 16 05:00:20 UTC 2023 , Edited by admin on Sat Dec 16 05:00:20 UTC 2023
|
PRIMARY | |||
|
6918257
Created by
admin on Sat Dec 16 05:00:20 UTC 2023 , Edited by admin on Sat Dec 16 05:00:20 UTC 2023
|
PRIMARY |